Vancouver, British Columbia, May 9, 2022 – Global Wellness Strategies Inc. (CSE:GWS) (OTCQB:GWSFF) (Frankfurt:O3X4) (“Global” or the “Company”) welcomes world-renowned Dr. Sud Agarwal as the chief medical advisor to lead the advisory team. His experience and expertise in the psychedelic industry will contribute significantly to our efforts in the space moving forward.
Dr. Agarwal is a co-founder of Shanti Therapeutics based in Australia, a company focused on pharmaceutical grade psychedelic solutions that Global Wellness recently acquired from Cannvalate Pty Ltd. Shanti is focused on psychedelic MDMA-based drug development and solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development.
Sud is a pioneer and a global first-mover in the cannabis space, a key influencer and an awarded cannabinoid research expert and an experienced listed company executive with deep investment networks. He is also a board member and executive of a number of public and private companies. Additionally, Dr. Agarwal is a specialist anesthesiologist and expert in FDA novel drug development. He has extensive experience in all phases of clinical trials for novel drugs. He has a proven ability to realize value from the companies he runs and/or invests in.
“We are honored to have Sud serve as a medical advisor and chair the advisory board, and we look forward to his invaluable strategic advice as we continue to grow Global Wellness and enter the psychedelic industry through our acquisition of Shanti Therapeutics. I could not ask for a more committed and valuable partner to Global Wellness.” remarked Global Wellness Strategies CEO, Meris Kott.
About Global Wellness Strategies
Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.
For further information visit websites:
Or Contact Meris Kott CEO 604.484.0355 or email to [email protected]
Further information about the Company is available on www.SEDAR.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
